Results 81 to 90 of about 5,456,142 (288)

NAFLD becomes MASLD, frequency & characteristics of non obese metabolic dysfunction associated steatotic liver disease (MASLD) among patients seeking care at a tertiary medical facility

Journal of the Pakistan Medical Association
Objective: To determine the frequency and clinical characteristics of non-obese metabolic dysfunction-associated steatotic liver disease, distinguishing it from simple steatosis without metabolic dysfunction. Method: The cross-sectional, observational
Sumerah Jabeen, Fivzia Farooq Herekar, angbeen Aqeel, Manzoor Hussain   +3 more
doaj   +1 more source

Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE) [PDF]

, 2007
Liver function tests (LFTs) are routinely performed in primary care, and are often the gateway to further invasive and/or expensive investigations.
David McLernon, McLernon, D, Donnan, Peter T, William Rosenberg, Sullivan, FM, Ryder, S, Donnan, PT, Roderick, Paul, Dillon, John F.; id_orcid, Rosenberg, William, McLernon, David, Paul Roderick, Steinke, Douglas, Donnan, Peter T.; id_orcid, Peter T Donnan, Ryder, Stephen, Sullivan, Frank M, Dillon, John F, Rosenberg, W, Frank M Sullivan, Stephen Ryder, Steinke, D, Dillon, JF, Dillon, John F., Sullivan, Frank M., John F Dillon, Douglas Steinke, Donnan, Peter T., Roderick, P, Steinke, Douglas; id_orcid, Roderick Paul, Sullivan Frank M, Dillon John F, Donnan Peter T, McLernon David, Steinke Douglas, Rosenberg William, Ryder Stephen   +37 more
core   +2 more sources

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source

Diagnostic Accuracy of Shear Wave Elastography for the Assessment of Congestive Liver Disease in Patients With Structural Heart Disease

Journal of Clinical Ultrasound, EarlyView.
Shear wave elastography demonstrated moderate diagnostic accuracy for detecting congestive liver disease in patients with structural heart disease. Increased liver stiffness was associated with echocardiographic markers of venous congestion, supporting the concept that elastography may serve as a noninvasive marker of cardiohepatic interaction ...
Edinéia Camargo Dziadzio, Maria Angelica Jungles Malikoski, Eduardo Henrique Bonotto, Sandra Monica Tochetto, Marco Stephan Lofrano‐Alves   +4 more
wiley   +1 more source

Shifting cell death modes in hepatic steatosis: from apoptosis to necroptosis

Endocrine Journal
In the liver, hepatocyte death occurs during the regeneration process following injury. While hepatocyte death triggers regeneration through hepatocyte proliferation in the non-steatotic liver, it impairs this process in the steatotic liver.
Yuka Inaba, Kohsuke Tsuchiya, Hiroshi Inoue   +2 more
doaj   +1 more source

PFAS exposure modulates mitochondrial susceptibility in steatotic hepatocytes

International audiencePer- and polyfluoroalkyl substances (PFAS) are highly persistent environmental pollutants that bioaccumulate in living organisms and are increasingly implicated in metabolic dysfunction-associated steatotic liver disease (MASLD ...
Barbosa, João Marcos G, Valgueblasse, Lorane, Nguyen, Anh Hoang, Oresic, Matej, Castro-Alves, Victor, Alijagic, Andi, Hyotylainen, Tuulia   +6 more
core   +1 more source

Farewell to the term ‘non-alcoholic fatty liver disease’

, 2023
After years of debate, the nomenclature non-alcoholic fatty liver disease (NAFLD) has been changed to metabolic dysfunction–associated steatotic liver disease, or MASLD (figure 1).
Mortimore, G.
core  

Interleukin‐37 Enhances Liver NK Cell Cytotoxicity and Improves Recurrence‐Free Survival in Hepatocellular Carcinoma Patients

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Introduction Hepatocellular carcinoma (HCC) remains a major cause of cancer‐related mortality worldwide, and postoperative recurrence continues to limit long‐term survival. Liver‐resident natural killer (NK) cells are key effectors of antitumor immunity in the hepatic microenvironment. Interleukin‐37 (IL‐37), an anti‐inflammatory cytokine, has
Yuki Imaoka, Masahiro Ohira, Yuka Tanaka, Toshihiro Nakayama, Miho Akabane, Shinichiro Yokota, Sheri M. Krams, Olivia M. Martinez, Carlos O. Esquivel, Kazunari Sasaki, Hideki Ohdan   +10 more
wiley   +1 more source

The association between physical activity and metabolic dysfunction–associated steatotic liver disease: Evidence from the National Health and Nutrition Examination Survey and UK Biobank

Journal of International Medical Research
Objective There is limited prospective evidence on the association of physical activity with metabolic dysfunction–associated steatotic liver disease. We aimed to use data from two major databases to systematically quantify the correlation of physical ...
Yiping Shen, Meiyu Chen, Shiqi Zhu, Jiaxi Lin, Lihe Liu, Chengyi Zhu, Jinzhou Zhu, Chunfang Xu   +7 more
doaj   +1 more source

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease

Microorganisms
The gut microbiota has emerged as a critical player in metabolic and liver health, with its influence extending to the pathogenesis and progression of steatotic liver diseases.
Andrea Pasta, Elena Formisano, Francesco Calabrese, Elisa Marabotto, Manuele Furnari, Giorgia Bodini, Maria Corina Plaz Torres, Livia Pisciotta, Edoardo Giovanni Giannini, Patrizia Zentilin   +9 more
doaj   +1 more source